Clinical Trials Browser

Phase 2/3 × Completed × anlotinib × Clear all

NCT02332499 2019-05-21

ALTER0703

Phase 2/3 Completed

Gastrointestinal

Colorectal Neoplasms

NCT02586350 2019-05-21

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Phase 2/3 Completed

Carcinoma, Medullary

NCT02388919 2017-09-18

ALTER0303

Phase 2/3 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms